Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance for Fabhalta® (iptacopan ...

A combination treatment has shown promise for treating a rare blood disease, according to a clinical trial published in the ...

They are thus reported to be useful for the treatment of age-related macular degeneration, schizophrenia, atypical hemolytic uremic syndrome, membranous nephropathy, myasthenia gravis, paroxysmal ...

SAR-443809 is under clinical development by Sanofi and currently in Phase I for Paroxysmal Nocturnal Hemoglobinuria. According to GlobalData, Phase I drugs for Paroxysmal Nocturnal Hemoglobinuria have ...

A 19-year-old woman diagnosed with two blood disorders is fighting for her life — and a lack of funds could result in death. Briana Pires, from Spokane, Washington — who recently pulled out of college ...

Through this approval, Eculizumab is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS) to inhibit complement – ...

Eculizumab is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS) to inhibit complement–mediated thrombotic ...

Reports $709 million in preliminary1 full-year 2024 U.S. net product revenues $611 million in SYFOVRE® U.S. net product revenues, including $167 million in 4Q 2024$98 million in EMPAVELI® U.S. net ...

Seropositive NMOSD incidence was found to be higher in this study's cohort than in many contemporary studies. The prevalence rate of neuromyelitis optica spectrum disorder (NMOSD) was significantly ...